# Incept BioSystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/incept-biosystems

- Industry: Biotechnology
- Headquarters: Ann Arbor, US
- Website: www.inceptbio.com
- Total disclosed funding: $6.5M
- Latest round: Series A (Mar 31, 2007)
- Investors on record: 3

## About

Incept BioSystems is a biotechnology firm dedicated to developing advanced therapeutics and diagnostic tools that address significant health challenges, focusing on the unique needs of patients and healthcare providers.Founded in 2005 and headquartered in Ann Arbor, US, Incept BioSystems specializes in biotechnology solutions targeting critical health challenges. They have secured a total of USD 3.30 mn across 5 deals, with the latest funding round being a Series A on December 15, 2010, backed by Plymouth Growth Partners. In December 2010, Orgio agreed to acquire all assets of Incept Biosystems, a transaction completed in January 2011.Incept Bio specializes in providing innovative biotechnology solutions aimed at addressing critical health challenges through the development of advanced therapeutics and diagnostic tools. Their core offerings include proprietary biopharmaceuticals designed for targeted treatment of complex diseases, alongside cutting-edge diagnostic platforms that enhance disease detection and monitoring. These products have been engineered to improve patient outcomes by facilitating personalized treatment strategies tailored to the individual needs of patients in various therapeutic areas, including oncology and rare genetic disorders. Incept Bio primarily serves hospitals, research institutions, and healthcare providers across North America and Europe, catering to a diverse client base that includes both public and private healthcare sectors, ensuring that their technologies reach end-users such as healthcare professionals and patients in need of advanced medical solutions.Incept Bio generates revenue through a structured model that includes direct sales to healthcare institutions and partnerships with research organizations. Revenue streams are established through the sale of their flagship biopharmaceutical products and diagnostic services, which are offered under competitive pricing plans tailored to meet the needs of institutional buyers. The company engages in B2B transactions, providing bulk purchasing options for hospitals and clinics, while also forming strategic alliances with pharmaceutical companies to enhance distribution channels and market reach. Additionally, subscription-based models may be implemented for ongoing access to their diagnostic platforms, ensuring that clients benefit from the latest advancements in technology as they become available. The revenue framework is designed to support the continuous development and refinement of Incept Bio's product offerings, fostering innovation and long-term growth.Incept BioSystems is focused on expanding its product lineup with new therapeutics and diagnostic tools aimed for release in upcoming years. They are pursuing market expansion into Europe and Asia by 2015, enhancing their global footprint. The recent Series A funding round will be utilized to support these initiatives and to ensure the development and commercialization of their innovative products.

## Funding rounds

- Series A, Mar 31, 2007, $3.3M — Straylight Capital
- Series A, Dec 28, 2006, $3.2M — Venture Investors, Straylight Capital, Angel Healthcare Investors

## Investors

- Venture Investors — Series A
- Straylight Capital (https://capitalatlas.ai/funds/straylight-capital) — Series A
- Angel Healthcare Investors — Series A